𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Quantitative analysis of drug handling by the kidney using a physiological model of renal drug clearance

✍ Scribed by I. Janků; K. Zvara

Publisher
Springer
Year
1993
Tongue
English
Weight
508 KB
Volume
44
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A physiologically based kidney model for
A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog
✍ Sandra P. A. Boom; Ineke Meyer; Alfons C. Wouterse; Frans G. M. Russel 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 2 views

Ranitidine renal clearance was investigated in the beagle dog with or without concomitant infusion of cimetidine or probenecid. Ranitidine was excreted mainly by renal tubular secretion. Plasma clearance was reduced by probenecid from 198 9 47 to 119 9 41 mL min -1 (mean9 S.D.); renal clearance was

A priori prediction of tissue:plasma par
A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery
✍ Patrick Poulin; Frank-Peter Theil 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB 👁 3 views

The tissue:plasma (P t:p ) partition coefficients (PCs) are important drugspecific input parameters in physiologically based pharmacokinetic (PBPK) models used to estimate the disposition of drugs in biota. Until now the use of PBPK models in early stages of the drug discovery process was not possib

Utility of a physiologically–based pharm
Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice
✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4